Zhejiang Medicine CoSHSE:600216 -0.83%81 PB Ratio is 1.03 as of Jul. 08, 2026, which is 29% below its 10-year median of 1.45. GuruFocus rates SHSE:600216 with a GF Score™ of 81/100 and a GF Value™ of ¥13.81 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 919 Drug Manufacturers companies, Zhejiang Medicine Co ranks better than 75.08% on this metric.
Zhejiang Medicine Co Ltd stock PB Ratio (=1.05) is close to 2-year low of 0.97.
The historical rank and industry rank for Zhejiang Medicine Co's PB Ratio or its related term are showing as below:
SHSE:600216'
s PB Ratio Range Over the Past 10 Years
Min: 0.87 Med: 1.45 Max: 2.68
Current: 1.03
During the past 13 years, Zhejiang Medicine Co's highest PB Ratio was 2.68. The lowest was 0.87. And the median was 1.45.
SHSE:600216's PB Ratio is ranked better than 75.08% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.91
vs SHSE:600216: 1.03
During the past 12 months, Zhejiang Medicine Co's average Book Value Per Share Growth Rate was 1.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhejiang Medicine Co was 64.30% per year. The lowest was 0.20% per year. And the median was 6.35% per year.
Back to Basics: PB Ratio
Zhejiang Medicine Co (SHSE:600216) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhejiang Medicine Co PB Ratio Related Terms
Zhejiang Medicine Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Zhejiang Medicine Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Medicine Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Medicine Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Medicine Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhejiang Medicine Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhejiang Medicine Co (SHSE:600216) has a PB Ratio of 1.03 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Medicine Co and its competitors. This is 29% below median its historical median of 1.45. Over the past decade, Zhejiang Medicine Co's PB Ratio has ranged from 0.87 to 2.68. According to the industry distribution chart, Zhejiang Medicine Co ranks #229 out of 919 companies in the Drug Manufacturers industry, placing it in the top 24.9%.
Is Zhejiang Medicine Co's PB Ratio too high?
Zhejiang Medicine Co's current PB Ratio of 1.03 is 29% below median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.87 to a high of 2.68. The Drug Manufacturers industry median PB Ratio is 1.91. Zhejiang Medicine Co's value of 1.03 is 46.1% below this industry median. Based on the distribution chart, Zhejiang Medicine Co ranks #229 out of 919 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Medicine Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Medicine Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zhejiang Medicine Co ranks #229 out of 919 companies for PB Ratio. This places Zhejiang Medicine Co in the top 25% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.91. Zhejiang Medicine Co's value of 1.03 is 46.1% below this benchmark. Historically, Zhejiang Medicine Co's own PB Ratio has ranged from 0.87 to 2.68 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 1.91, Zhejiang Medicine Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.91, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Medicine Co's current PB Ratio of 1.03 is 46.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Medicine Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Medicine Co's current PB Ratio is 1.03, which is 29% below median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Medicine Co (SHSE:600216) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.81, compared to a current price of ¥12.00 — trading 13.1% below its estimated fair value. The current PB Ratio is 1.03, which is 29% below median its 10-year median of 1.45 and 46.1% below the Drug Manufacturers industry median of 1.91. Zhejiang Medicine Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhejiang Medicine Co (SHSE:600216), the current PB Ratio is 1.03 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Medicine Co (SHSE:600216) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Medicine Co stock appears to be undervalued.
The current stock price of ¥12.00 is trading 13.1% below its estimated GF Value™ of ¥13.81.
GuruFocus considers Zhejiang Medicine Co to be Modestly Undervalued.
Key valuation signals for SHSE:600216:
PB Ratio: 1.03 (29% below median its 10-year median of 1.45)
GF Value™: ¥13.81 vs. price of ¥12.00 (13.1% below fair value)
Industry Position: 46.1% below the Drug Manufacturers median (#229 of 919)
No single metric tells the full story. See the SHSE:600216 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Medicine Co Ltd is a china-based pharmaceutical company. The company manufactures fat-soluble vitamins, vitamins, quinolones, and antibiotic-resistant antibiotics, vitamin E, natural vitamin E, beta-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin.
81GF Score
Get the complete analysis for SHSE:600216
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600216 has been successfully added to your 
